Organ transplants, when available and when medically successful,
tend to give the recipients a shot at longer, healthier lives.

Patients who don't get the liver transplants they need
are likely to die in 1-2 years.

Those who need but don't get kidney transplants
can spend 5-10 years on dialysis.

SmartPerfusion is developing its VasoWave™ system with the goal of improving the terrible odds
now facing patients who need organ transplants. Smart Perfusion's hope is to broaden the pool of viable organs
available to patients who need transplants.

If successful, the patented and patent-pending VasoWave™ technology SmartPerfusion has created (which is an investigative device still undergoing human clinical trials and subject to FDA review and approval) is expected to facilitate recovery of viable organs from 10,000 to 50,000 (or more) additional donors each year, plus reduce the number of organs presently discarded.

REVOLUTIONARY next Gold Standard with Easy, Evolutionary Implementation

VasoWave video presentation 

Smart Perfusion, LLC has created a revolutionary organ preservation system that may make a greater number of viable human organs available to the tens of thousands of patients suffering from failure of the kidney, liver, heart, pancreas and other organs.

The VasoWave™ system may provide significant capabilities for organ assessment, conditioning, restoration, preservation and transport for transplant. Our mission, subject to clinical trials and FDA clearance, is to:

  1. Make a greater number of viable organs available to the tens of thousands of patients who urgently need them.
  2. Provide opportunity for transplant surgeons and their medical centers to produce higher revenues
    with less strain on medical professionals.
  3. Reduce the overall cost of health care related to organ transplantation.

Fewer than 20% of patients with failing organs receive a transplant. Lost revenue to the transplant community is over $1 billion per year in the U.S. Cost to taxpayers is over $20 billion per year. Learn more about the transplant industry and technology.

Only a small fraction of potentially available organs are deemed acceptable and recovered for transplant. As a result, the overwhelming need for organ transplants has become a medical crisis!

"Vasowave™ has the potential to do for transplant in the 21st century what the heart-lung bypass machine
did for cardiac surgery in the turn of the last century."
-- David Gerber, MD

Read about Smart Perfusion's next gold standard for organ transplantation.

Our management team has technical, medical, transplant and
broad business experience to deliver this revolutionary technology.

 

NOTE: VasoWave™ is an investigative device in the preclinical stage of development. It has not yet been tested extensively on humans or approved for commercial sale by the FDA or by any other regulatory body.